The Abatacept Prevention Study has two phases: treatment and follow up.
In the treatment phase, participants make three visits to a TrialNet site in the first four weeks (every other week); then one study visit a month for 11 months. Each visit takes about 2 hours and includes a 30-minute infusion, followed by one hour of observation.
In the follow up phase, participants return for tests and monitoring two times a year. Visits last about 2.5 hours.
Half the people in the study will get the study drug; the other half will get a placebo (looks like the study drug but is inactive). A computer randomly selects who gets the study drug, and no one knows who is in which group until the end of the study.
Regardless of which group you are in, you play an important role in advancing T1D research for the immediate study and well into the future. Once the study is over, blood samples from participants in the placebo arm of the study are used in other studies looking to answer questions about how T1D progresses and how to stop it.
All study participants receive close monitoring. If you develop T1D, our tests will likely show this before you have any symptoms. For people taking part in T1D research, the risk of diabetic ketoacidosis (DKA) at diagnosis drops from 30% to less than 4%. DKA is a serious condition that can be life-threatening. With early notification, you will be able to see your doctor and start taking insulin before you feel sick.
If there aren’t any studies for newly diagnosed T1D that are right for you, we will invite you to take part in monitoring.
Our T1D Family: The Eyth's from Type 1 Diabetes TrialNet on Vimeo.